Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDiseaseAdvances in myelodysplastic syndromes: promising novel agents and combination strategies
Madanat Y, Xie Z, Zeidan A. Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Expert Review Of Hematology 2023, 16: 51-63. PMID: 36620919, DOI: 10.1080/17474086.2023.2166923.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeMultiple novel agentsMyelodysplastic syndromeNovel agentsClinical trialsTreatment optionsPhase III clinical trialsSelect clinical trialsLow-risk diseaseClonal hematopoietic stem cell neoplasmHigh-risk diseaseBest treatment optionHematopoietic stem cell neoplasmsInnate immune systemStem cell neoplasmMechanism of actionHMA therapyEarly safetyTreatment paradigmEfficacy dataCell neoplasmsDrug combinationsClinical developmentUnmet needImmune system